Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. by Scott, Emma C. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medical Oncology Faculty Papers Department of Medical Oncology
10-1-2016
Post-Transplant Outcomes in High-Risk
Compared with Non-High-Risk Multiple
Myeloma: A CIBMTR Analysis.
Emma C. Scott
Oregon Health and Science University
Parameswaran Hari
Medical College of Wisconsin
Manish Sharma
Thomas Jefferson University, manish.sharma@jefferson.edu
Jennifer Le-Rademacher
Medical College of Wisconsin
Jiaxing Huang
Medical College of Wisconsin
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Part of the Oncology Commons
Recommended Citation
Scott, Emma C.; Hari, Parameswaran; Sharma, Manish; Le-Rademacher, Jennifer; Huang, Jiaxing;
Vogl, Dan; Abidi, Muneer; Beitinjaneh, Amer; Fung, Henry; Ganguly, Siddhartha; Hildebrandt,
Gerhard; Holmberg, Leona; Kalaycio, Matt; Kumar, Shaji; Kyle, Robert; Lazarus, Hillard; Lee,
Cindy; Maziarz, Richard T.; Meehan, Kenneth; Mikhael, Joseph; Nishihori, Taiga; Ramanathan,
Muthalagu; Usmani, Saad; Tay, Jason; Vesole, David; Wirk, Baldeep; Yared, Jean; Savani, Bipin N.;
Gasparetto, Cristina; Krishnan, Amrita; Mark, Tomer; Nieto, Yago; and D'Souza, Anita, "Post-
Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR
Analysis." (2016). Department of Medical Oncology Faculty Papers. Paper 78.
https://jdc.jefferson.edu/medoncfp/78
Authors
Emma C. Scott, Parameswaran Hari, Manish Sharma, Jennifer Le-Rademacher, Jiaxing Huang, Dan Vogl,
Muneer Abidi, Amer Beitinjaneh, Henry Fung, Siddhartha Ganguly, Gerhard Hildebrandt, Leona Holmberg,
Matt Kalaycio, Shaji Kumar, Robert Kyle, Hillard Lazarus, Cindy Lee, Richard T. Maziarz, Kenneth Meehan,
Joseph Mikhael, Taiga Nishihori, Muthalagu Ramanathan, Saad Usmani, Jason Tay, David Vesole, Baldeep
Wirk, Jean Yared, Bipin N. Savani, Cristina Gasparetto, Amrita Krishnan, Tomer Mark, Yago Nieto, and Anita
D'Souza
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medoncfp/78
Post-transplant outcomes in high-risk compared to non-high risk 
multiple myeloma, a CIBMTR analysis
Emma C. Scott1, Parameswaran Hari2, Manish Sharma3, Jennifer Le-Rademacher2,4, 
Jiaxing Huang2, Dan Vogl5, Muneer Abidi6, Amer Beitinjaneh7, Henry Fung8, Siddhartha 
Ganguly9, Gerhard Hildebrandt10, Leona Holmberg11, Matt Kalaycio12, Shaji Kumar13, 
Robert Kyle13, Hillard Lazarus14, Cindy Lee15, Richard T. Maziarz16, Kenneth Meehan17, 
Joseph Mikhael18, Taiga Nishihori19, Muthalagu Ramanathan20, Saad Usmani21, Jason 
Tay22, David Vesole23, Baldeep Wirk24, Jean Yared25, Bipin N. Savani26, Cristina 
Gasparetto27, Amrita Krishnan28, Tomer Mark29, Yago Nieto30, and Anita D’Souza2
1Center for Hematologic Malignancies, The Knight Cancer Institute, Oregon Health and Science 
University, Portland, OR 2CIBMTR (Center for International Blood and Marrow Transplant 
Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 3Department 
of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 
4Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, 
Milwaukee, WI 5Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 6Division 
of BMT, Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 
7University of Miami, Miami, FL 8Department of Medical Oncology, Fox Chase Cancer Center, 
Temple Health, Philadelphia, PA 9Blood and Marrow Transplantation, University of Kansas 
Medical Center, Kansas City, KS 10University of Kentucky Chandler Medical Center, Lexington, 
KY 11Fred Hutchinson Cancer Research Center, Seattle, WA 12Cleveland Clinic Foundation, 
Cleveland, OH 13Mayo Clinic Rochester, Rochester, MN 14Seidman Cancer Center, University 
Hospitals Case Medical Center, Cleveland, OH 15Royal Adelaide Hospital, Adelaide, SA, Australia 
16Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health 
and Science University, Portland, OR 17Dartmouth Hitchcock Medical Center, Lebanon, NH 
18Mayo Clinic Arizona and Phoenix Children’s Hospital, Scottsdale, AZ 19Department of Blood 
and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 
20Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical 
Center, Worchester, MA 21Department of Hematology-Medical Oncology, Levine Cancer Institute, 
Carolinas HealthCare System, Charlotte, NC 22University of Ottawa, Ottawa, Canada 23John 
Theurer Cancer Center at Hackensack UMC, Hackensack, NJ 24Division of Bone Marrow 
Transplant, Seattle Cancer Care Alliance, Seattle, WA 25Blood & Marrow Transplantation 
Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer 
Corresponding author: Anita D’Souza, MD, MS, CIBMTR, Medical College of Wisconsin, Milwaukee, WI 53226, 
andsouza@mcw.edu, Phone: 414-805-0700, Fax: 414-805-0714. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
This work was presented in part as a poster at the 57th Annual Meeting of the American Society of Hematology, 2015.
HHS Public Access
Author manuscript
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 October 01.
Published in final edited form as:
Biol Blood Marrow Transplant. 2016 October ; 22(10): 1893–1899. doi:10.1016/j.bbmt.2016.07.007.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Center, University of Maryland 26Division of Hematology/Oncology, Department of Medicine, 
Vanderbilt University Medical Center, Nashville, TN 27Duke University Medical Center, Durham, 
NC 28City of Hope National medical Center, Duarte, CA 29Department of Medicine, Weill Cornell 
Medical College, New York, NY 30MD Anderson Cancer Center, Houston, TX
Abstract
Conventional cytogenetics and interphase fluorescence in-situ hybridization (FISH) identify a 
high-risk multiple myeloma (HRM) population characterized by poor outcomes. We analyzed 
these differences among HRM versus non-HRM after upfront autologous hematopoietic cell 
transplantation (autoHCT). Between 2008 and 2012, 715 patients with multiple myeloma with 
FISH and/or cytogenetic data with upfront autoHCT were identified in the Center for International 
Blood and Marrow Transplant Research database. HRM was defined as del17p, t(4;14), t(14;16), 
hypodiploidy (< 45 chromosomes excluding -Y) or chromosome 1 p and 1q abnormalities; all 
others were non-HRM. Among 125 (17.5%) HRM patients, induction with bortezomib and 
immunomodulatory agents (imid) was higher compared to non-HRM (56% vs 43%, p <0.001) 
with similar pre-transplant complete response (CR) (14% vs 16%, p 0.1). At day-100 post-
transplant, ≥ very good partial response was 59% in HRM and 61% in non-HRM (p=0.6). More 
HRM patients received post-transplant therapy with bortezomib and imids (26% vs 12%, 
p=0.004). Three-year post-transplant progression-free (PFS) and overall survival (OS) in HRM 
versus non-HRM were 37% vs 49%, p <0.001 and 72% vs 85%, p <0.001 respectively. At 3-years, 
PFS for HRM with and without post-transplant therapy was 46(95% confidence interval 33–59)% 
versus 14(4–29)% and in non-HRM with and without post-transplant therapy 55(49–62)% versus 
39(32–47)%; OS for HRM with and without post-transplant therapy was 81(70–90)% versus 
48(30–65)% compared to 88(84–92)% and 79(73–85)% in non-HRM with and without post-
transplant therapy respectively. Among patients receiving post-transplant therapy, there was no 
difference in OS between HRM and non-HRM (p 0.08). In addition to HRM, higher stage, <CR 
pre-transplant, lack of post-transplant therapy and African-American race were associated with 
worse OS. In conclusion, we show HRM patients achieve similar day-100 post-transplant 
responses compared to non-HRM, but these responses are not sustained. Post-transplant therapy 
appeared to improve the poor outcomes of HRM.
Keywords
Multiple myeloma; Autologous HSCT; High risk; maintenance
Introduction
The heterogeneous clinical course of multiple myeloma is partially related to high risk 
prognostic molecular markers in the plasma cell clone. Using conventional metaphase 
cytogenetics and interphase fluorescent in-situ hybridization (FISH), 20–25% of myeloma 
patients are found to have high-risk myeloma (HRM) which is associated with a poor 
prognosis.1, 2 The International Myeloma Working Group (IMWG) 2014 consensus defines 
a combined high risk model incorporating International Staging System II or III and del 
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(17p) or t(4;14). High-risk patients with these markers are expected to survive a median of 2 
years despite novel agents, compared to more than 10 years for low-risk patients.3 Kapoor et 
al found that patients with cytogenetic abnormalities did worse after autoHCT.4 Other high 
risk cytogenetic/ FISH abnormalities that are associated with worse outcomes include 
t(14;16)5, 6 and chromosome 1 abnormalities (1q21 amplification, 1p deletion)5, 7, although 
conflicting data exist regarding the prognostic significance of these groups.5, 7–12
Autologous hematopoietic cell transplant (autoHCT) is available broadly, improves survival 
in myeloma patients, and is currently considered a standard of care for transplant-eligible 
patients; however data on the benefits of auto-HCT in HRM are lacking. Trends towards 
improved survival have been reported by University of Arkansas for Medical Sciences 
Myeloma Institute with the Total Therapy program, where tandem autoHCT has been 
preceded by induction and followed by consolidation/maintenance including bortezomib in 
more recent years.13 Approaches to post-transplant consolidation and maintenance 
specifically for HRM are evolving and range from single agent lenalidomide or bortezomib 
to triplet therapy combining these agent with dexamethasone.14–16 We undertook this study 
to examine the role of autoHCT with HRM in the era of novel agents and post-transplant 
therapies. We used the Center for International Blood and Marrow Transplant Research 
(CIBMTR) database to analyze patient and disease characteristics, response to induction 
therapies as well as autoHCT and post-transplant outcomes among patients undergoing 
autoHCT for multiple myeloma from 2008–2012.
Methods
Data source
The CIBMTR is a prospectively maintained transplant database that captures transplant data 
from over 420 transplant centers worldwide. Data are submitted to a statistical center at the 
Medical College of Wisconsin in Milwaukee. Participating centers are required to report all 
transplants consecutively; patients are followed longitudinally and compliance is monitored 
by on-site audits. Computerized checks for discrepancies, physicians' review of submitted 
data, and on-site audits of participating centers ensure data quality. Observational studies 
conducted by the CIBMTR are performed in compliance with all applicable federal 
regulations pertaining to the protection of human research participants. Protected Health 
Information used in the performance of such research is collected and maintained in 
CIBMTR’s capacity as a Public Health Authority under the HIPAA Privacy Rule.
Patient Selection
Adults who underwent first autologous hematopoietic cell transplantation for multiple 
myeloma between January 1, 2008 and December 31, 2012 with high dose melphalan 
conditioning within 12 months of diagnosis with available molecular risk results (by FISH 
and/or cytogenetics) were the subjects of this retrospective observational study. We 
identified 715 patients limited to centers reporting at least 10% high risk patients in order to 
reduce center variability in evaluation of high risk status. Among them 125 patients were 
classified as high-risk myeloma (HRM) defined by the presence of deletion 17p13 alone 
(n=28), t(4;14) alone (n=28), t(14;16) alone (n=5), hypodiploid alone (n=12), chromosome 
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1q amplification or 1p deletion (n=25) and a combination of more than 1 of aforementioned 
markers (n=27). Chromosome 1 abnormalities included amplification of 1q (n=21), deletion 
of 1p (n=3), and both 1q amp plus 1p del (n=1). Physicians blinded to the outcome reviewed 
the FISH and cytogenetic reports from each reporting institution.
Outcomes and definitions
The outcomes of interest included overall survival (OS), progression-free survival (PFS) and 
relapse/progression of multiple myeloma after transplant. Overall survival was defined as 
death from any cause with censoring of surviving patients at last follow-up; PFS was defined 
as survival without progressive disease or relapse from complete response. Patients alive and 
without progression/relapse were censored at last follow-up. Relapse/progression was 
defined as time to first evidence of recurrence or progression of multiple myeloma and 
summarized by the cumulative incidence estimate with transplant-related mortality as the 
competing risk.
Statistical analysis
Patient, disease and transplant-related variables and outcomes of interest were evaluated. 
Estimates of outcomes were reported as probabilities with 95% confidence intervals (95% 
CI). The probability of OS and PFS was calculated with the Kaplan-Meier estimator. 
Multivariable analysis was performed using Cox proportional hazards regression. High-risk 
status was considered the main effect in the multivariable analysis. Other factors tested in 
the analysis are listed in Supplementary table 1. The assumption of proportional hazards was 
tested for each variable, and factors violating the proportionality assumption were adjusted 
by stratification. A stepwise model building approach was used to develop models for OS, 
PFS and relapse/progression. A p-value of <0.05 was considered statistically significant. 
Statistical analysis was performed using SAS v 9 (Cary, NC).
Results
Baseline patient and disease characteristics as well as induction and maintenance regimens 
are available in table 1. Median follow up was 36 months for HRM and 44 months for non-
HRM. The median age, Karnofsky and HCT comorbidity index scores were similar among 
cohorts. When compared to non-HRM, the HRM cohort was associated with higher stage at 
diagnosis (43% vs 28% p=0.003). More HRM patients received induction with bortezomib 
and immunomodulatory drug (imid) combinations (56% vs 43%, p <0.001) and had a 
similar complete response rates prior to transplant (14% vs 16%, p = 0.1).
Day 100 responses
At 100 day post-transplant, similar numbers of patients had achieved a response in the 2 
groups. The >/= partial responses (overall response rate) for HRM and non-HRM groups 
were 85 and 84% respectively and >/= very good partial responses (VGPR) in the HRM and 
non-HRM groups were 59 and 61% respectively. Complete and stringent complete responses 
(CR/sCR) were 31 vs 30% and VGPR rates were 28 and 31% in the HRM and non-HRM 
groups respectively.
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Post-transplant therapies
Based on center reporting, we were unable to discern differences between consolidation and 
maintenance therapies and 'post-transplant therapy' was used to encompass all therapies used 
in the absence of relapse and/or progression after transplant. Patients with HRM were more 
likely to receive planned post-transplant therapy compared to non-HRM patients (71 vs 
66%, p= 0.004), with combined bortezomib and imid therapy used more frequently in HRM 
(26% vs 12%). While bortezomib monotherapy was used equally in both groups (2%), 
lenalidomide monotherapy was used more frequently in non-HRM patients (37%) compared 
to HRM patients (30%), p 0.004.
Disease control and survival outcomes
The median follow up of survivors in this cohort was 36 months for the HRM and 44 months 
for non-HRM groups. Median PFS and OS for HRM were 21 and 68 months; median PFS 
for non-HRM group was 36 months and OS was not reached. In the univariate analysis 
(Table 2) PFS at 1 year for HRM was 61% vs 82% for non-HRM, at 2 years PFS for HRM 
was 48% vs 64% for non-HRM, at 3 years PFS for HRM was 37% vs 49% for non-HRM 
and at 4 years from auto-HCT PFS was 25% for HRM vs 38% for non-HRM (p <0.001). 
Overall survival at 1 year from autoHCT was 89% for HRM vs 95% for non-HRM, at 2 
years OS was 81% for HRM vs 91% for non-HRM, at 3 years OS was 72% for HRM vs 
85% for non-HRM and at 4 years post autoHCT OS was 59% for HRM and 80% for non-
HRM (p <0.001), Figure 1. Univariate analysis of PFS and OS by type of cytogenetic 
abnormality is shown in table 4.
In the multivariable analysis (Table 3), HRM was independently associated with higher 
relapse rate (hazard ratio 1.82, 95% confidence interval 1.4–2.4, p < 0.0001) and overall 
mortality (HR 2.24, 95% CI 1.5–3.3, p < 0.0001), A deeper response status prior to 
transplant and planned post-transplant therapy (HR1.94, 95% CI 1.4–2.8, p = 0.001) 
independently reduced relapse, and improved PFS and OS. Higher stage at diagnosis and 
black race also adversely affected survival in this cohort.
Progressive disease was the predominant cause of death in both groups (87% vs 83%). 
Infection (3% vs 4%), organ failure (5% vs 3%) and secondary malignancy (0 vs 2%) rates 
were similar in HRM and non-HRM respectively.
Impact of post-transplant therapies on survival
Comparing survival of HRM versus non-HRM based on whether they received post-
transplant therapy or not, the 3 year post-transplant PFS for HRM receiving post-transplant 
therapy was 46(33–59)% compared to 14(4–29)% for HRM not receiving it (p-value 
<0.001). For non-HRM with post-transplant therapy, 3 year PFS was 55(49–62)% compared 
to 39(32–47)% for non-HRM without it (p-value 0.002). The 3-year OS for HRM with post-
transplant therapy was 81(70–90)% versus 48(30–65)% without (p-value <0.001), compared 
to non-HRM with post-transplant therapy 88(84–92)% versus 79(73–85)% without it (p-
value 0.02). Overall survival for HRM versus non-HRM without post-transplant therapy 
(Figure 1A) was significantly worse (p-value <0.0001) but not statistically significant for 
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HRM versus non-HRM on post-transplant therapy (p-value 0.08) (Figure 1B). Details of 
type of post-transplant therapy and outcomes are shown in Supplementary table.
Impact of chromosomal abnormalities on survival
Comparing survival based on specific chromosomal abnormalities, 3 year PFS for non-HRM 
was 49(45–54)%; 28 (11–50)% for t(4;14); 43(24–62)% for del 17p; 50(29–72)% for 
chromosome 1 abnormalities and 27(10–47)% for >1 high-risk marker (p<0.001). Three 
year OS for non-HRM was 85(81–88)%, 60(39–80)% for t(4;14); 78(57–93)% for del 17p; 
91(77–97)% for chromosome 1 abnormalities and 67(48–84)% for >1 high-risk marker 
(p<0.001) (Table 4 and Figure 2).
Discussion
We describe outcomes after upfront auto-HCT in a recent cohort of multiple myeloma 
patients with cytogenetic and FISH data available from the CIBMTR. We make a number of 
clinically important observations: 1) Despite having similar day 100 post-transplant 
responses, HRM patients have worse outcomes as early as 1 year post-auto HCT, 2) Certain 
molecular abnormalities are associated with worse outcomes than others in this cohort but 
the presence of more than 1 high-risk marker identifies a subgroup of patients that have the 
worst prognosis, 3) The 3 year PFS was similar in the non –HRM and chromosome one 
abnormality group, 4) Post-transplant therapies are associated with lower relapse rates, 
longer PFS and OS in both HRM and non-HRM groups, 5) The relative improvement in PFS 
and OS seen in HRM receiving post-transplant therapy is greater than the improvement seen 
in the non-HRM groups, however OS is clearly distinguishable visually among all 4 
categories (figure 1B) and 6) Black race is associated with worse OS than Whites without an 
association with worse relapse/progression or PFS in multivariable analysis.
The survival of multiple myeloma patients has significantly improved over the past two 
decades, however, this improvement has not been uniform, with some patients achieving 
long-term remissions and living for more than 10 years while others succumb to their 
disease and die within 3 years. This heterogeneity in outcomes is partially explained by the 
presence of high risk molecular markers.17
The definition of HRM has evolved over time as studies incorporating more detailed disease, 
patient and tumor specific markers are completed and the natural history of the disease has 
been examined.18 In the current era, while there is certainty regarding the poor prognostic 
significance of del (17p); the other cytogenetic abnormities are not equivocally poor across 
studies, and treatment with bortezomib appears to abrogate the poor prognosis associated 
with t(4;14). The International Myeloma Workshop 2011 consensus suggested that 
cytogenetic chromosome 13q deletion, t(4;14); del (17p); t(14;16) by FISH or cytogenetics 
should be considered high risk.19 The IMWG 2014 consensus defined a combined high risk 
model incorporating International Staging System II or III and del (17p) or t(4;14). Using 
this model, high-risk patients are projected to survive under 2 years despite novel agents 
while low-risk patients survive for more than 10 years.3, 5 Conflicting data exist regarding 
prognostic significance of t(14;16) whereby the Mayo Clinic6 and the Medical Research 
Council5 groups show that it is associated with poorer outcome, whereas the IFM studies8 
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did not show this. Similarly, conflicting data exist for chromosome 1 abnormalities (1q21 
amplification, 1p deletion and others). Some reports have shown amplification 1q21 to be an 
independent prognostic factor5, 7 whereas our data as well as others have not.1, 11 According 
to the IMWG, although its role as a poor prognostic factor is controversial, the lack of 
1q21amplification may be useful in identifying patients with good prognosis.3 Deletion of 
1p has also been shown to be an independent prognostic factor associated with shorter 
survival.9, 10, 12 In 2015, Palumbo, et al. published a ‘revised ISS’ incorporating serum 
LDH, cytogenetic abnormalities [del 17p, t(4;14) and t(14;16)] and ISS.20 In our study, stage 
was analyzed as a separate variable but because LDH at diagnosis was not reported 
uniformly, we could not analyze it. The depth of pre-transplant response is also associated 
with outcomes.21 In our study, we found similar results with stage, depth of pre-transplant 
response and presence of HRM associated with worse outcomes.
A previous CIBMTR study which assessed auto-HCT outcomes based on race in an older 
cohort (1995–2005) did not show any difference in outcomes among Blacks compared to 
Whites.22 The current study which assesses a more recent cohort does identify that despite 
no significant differences in relapse rates or PFS, black patients had worse overall survival 
than white patients. This finding was unexpected and should be investigated further.
Our study highlights the benefit of high dose therapy and the importance of post-transplant 
consolidation and/or maintenance therapies for HRM patients and suggests that worse 
outcomes due to HRM are mitigated by this strategy, with no difference in OS between 
HRM and non-HRM groups. Historically, the impact of induction and maintenance 
bortezomib on t(4;14) may overcome its poor prognosis; however the impact on del (17p) 
has been mixed.16, 23, 24 Lenalidomide maintenance has also been shown to be beneficial in 
HRM.14
This is the largest CIBMTR analysis addressing the impact of chromosomal abnormalities. 
However, limitations include the possibility of false negative FISH results, heterogeneous 
FISH methodology and variable plasma cell enrichment. Thus, it is possible that our non-
HRM cohort includes patients with HRM and the differences in outcomes that we show may 
be an under-estimation. We minimized this bias by excluding centers that reported a low 
number of high risk cases. Independent physician review of FISH and cytogenetic data when 
available were also conducted to ensure that center reporting was confirmed.
In conclusion, our results reveal worse outcomes for HRM after auto-HCT despite similar 
early responses and that patients with more than one high risk chromosomal abnormality 
fare particularly poorly, followed closely by t(4;14). In this cohort, patients with 
chromosome 1 abnormalities had similar outcomes to patients without high risk cytogenetic 
abnormalities, suggesting that single chromosome 1 abnormalities may not be considered 
high risk unless accompanied by other high risk cytogenetic abnormalities. Strategies to 
maintain early post-transplant responses such as consolidation and maintenance treatments 
should be considered in all HRM patients although the benefit of any particular therapy 
could not be gleaned from the current analysis due to the heterogeneity of post-autoHCT 
treatment strategies employed.
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Figure 1. 
A. Progression-free and (B) overall survival in HRM and non-HRM after autoHCT
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Figure 2. 
(A) Progression-free and (B) overall survival in non-HRM, t(4;14), del 17p, chromosome 1 
abnormalities, ≥ 2 high risk abnormalities after auto-HCT
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Table 1
Characteristics of patients
Variable HRM Non-HRM p-value
Number of patients (17%)125 (83%) 590
Median age at transplant, years (range) 58 (33–72) 58 (28–76) 0.91
Age >65 69 (55) 338 (57) 0.67
Male Gender
Race 0.55
  White 98 (78) 460 (78)
  Black 21 (17) 110 (19)
  Others1 5 (4) 12 (2)
  Unknown 1 (<1) 8 (1)
Karnofsky Score, < 90% 56 (45) 222 (38) 0.15
HCT-CI score, >3 19 (15) 92 (16) 0.62
Disease-related
Cytogenetic abnormality (conventional or
FISH)
High Risk
  t(4;14) only 28 (22) --
  t(14;16) only 5 (4) --
  del17p only 28 (22) --
  Hypodiploid only 12 (10) --
  Chromosome 1 abnormalities only 25 (20) --
  ≥2 High risks 27 (22) --
ISS/Durie-Salmon Stage III 54 (43) 167 (28) 0.003
Beta-2 microglobulin level at diagnosis,
≥3.5 mg/l
73 (58) 226 (38) <0.001
Serum albumin at diagnosis, < 3.5 g/dl 53 (42) 175 (30) 0.02
Hemoglobin at diagnosis, g/dl
  N Evaluable 121 562
  Median (range) 10 (3–17) 11 (1–18) <0.001
Serum creatinine ≥ 2 mg/dl at diagnosis 10 (3–17) 11 (1–18) 0.34
Treatment-related
Lines of chemotherapy 0.81
  1 102 (82) 476 (81)
  2 23 (18) 114 (19)
Pre-Transplant Chemotherapy <0.001
  IMID + Bort +/− Steroids 70 (56) 254 (43)
  IMID +/− Steroids 15 (12) 185 (31)
  Bort +/− Cytoxan +/− Steroids 27 (22) 88 (15)
  Others2 5 (4) 17 (3)
Disease status at transplant 0.11
  CR 17 (14) 92 (16)
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scott et al. Page 14
Variable HRM Non-HRM p-value
  VGPR 44 (35) 164 (28)
  PR 53 (42) 290 (49)
  SD 4 (3) 30 (5)
  Rel/prog 7 (6) 14 (2)
Time from diagnosis to transplant 0.84
  < 6 months 54 (43) 249 (42)
  6 – 12 months 71 (57) 341 (58)
Year of transplant 0.01
  2008 25 (20) 213 (36)
  2009 18 (14) 68 (12)
  2010 18 (14) 79 (13)
  2011 36 (29) 129 (22)
  2012 28 (22) 101 (17)
Post-transplant therapy 0.004
  Lenalidomide+Bortezomib+/−Steroid 33 (26) 72 (12)
  Lenalidomide+/− Steroid 37 (30) 218 (37)
  Bortezomib +/− Steroid 3 (2) 12 (2)
  Thalidomide +/− Steroid 3 (2) 9 (2)
  Others 0 4 (<1)
  No post-transplant therapy 36 (29) 200 (34)
  Unknown 13 (10) 75 (13)
Median follow-up of survivors (range),
months
36 (3–78) 44 (3–83)
1Asian (11), American Indian/Pacific Islander (5).
2VAD/similar (15), VDPACE (7).
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Table 2
Univariate analysis of outcomes
HRM, N=125
Prob (95% CI)
Non-HRM, N=590
Prob (95% CI)
p-value
Relapse <0.001
  1-year 38 (29–46)% 18 (15–21)%
  2-year 51 (42–60)% 35 (31–39)%
  3-year 62 (52–70)% 49 (44–53)%
  4-year 73 (61–82)% 61 (56–66)%
Progression free survival <0.001
  1-year 61 (53–70)% 82 (79–85)%
  2-year 48 (39–57)% 64 (60–68)%
  3-year 37 (28–47)% 49 (45–54)%
  4-year 25 (16–35)% 38 (33–43)%
Overall survival <0.001
  1-year 89 (82–94)% 95 (94–97)%
  2-year 81 (73–87)% 91 (89–93)%
  3-year 72 (63–80)% 85 (81–88)%
  4-year 59 (47–71)% 80 (76–84)%
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Table 3
Multivariate analysis of outcomes
Outcome Number Hazard ratio (95% CI) p-value
Relapse
HRM vs non-HRM 125 1.83 (1.41–2.36) <0.0001
Pre-transplant CR 109 1 <0.0001
    VGPR 208 1.2 (0.8–1.7) 0.3032
    PR 343 1.7 (1.2–2.3) 0.0014
    SD 34 2.0 (1.1–3.3) 0.0084
    Progression 21 3.2 (1.8–5.7) <0.0001
Planned post-transplant therapy 391 1 0.0002
    None 235 1.5 (1.2–1.9) 0.0002
    Missing 88 0.9 (0.6–1.3) 0.6177
Progression-free survival
HRM vs non-HRM 125 1.8 (1.4–2.4) <0.0001
Pre-transplant CR 109 1 <0.0001
    VGPR 208 1.2 (0.8–1.7) 0.3984
    PR 343 1.6 (1.1–2.2) 0.0026
    SD 34 1.8 (1.1–3.1) 0.0156
    Progression 21 3.0 (1.7–5.3) 0.0001
Planned post-transplant therapy 391 1 <0.0001
    None 235 1.6 (1.2–2.0) <0.0001
    Missing 88 0.9 (0.6–1.4) 0.6926
Overall survival
  HRM vs non-HRM 125 2.24 (1.53–3.27) <0.0001
  Black vs White 131 1.7 (1.1–2.5) 0.0061
  ISS/DSS III Yes vs No 221 1.8 (1.2–2.5) 0.0034
  Pre-transplant CR 109 1 0.0042
    VGPR 208 2.0 (1.0–3.8) 0.0244
    PR 343 2.2 (1.2–4.0) 0.0054
    SD 34 2.2 (0.8–5.4) 0.0996
    Progression 21 5.0 (2.1–11.3) 0.0001
Planned post-transplant therapy 391 1 0.0010
    None 236 1.9 (1.3–2.8) 0.0002
    Missing 88 1.3 (0.7–2.4) 0.2892
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